

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BeiGene USA, Inc. and BeiGene, LTD.,
Petitioners,

v.

Pharmacyclics LLC
Patent Owner.

PGR2024-00009
U.S. PATENT NO. 11,672,803

PETITIONERS' UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Petitioners BeiGene USA, Inc. and BeiGene, LTD., respectfully submits the following updated exhibit list:

<u>Exhibit</u>	<u>Description</u>
1001	U.S. Patent No. 11,672,803
1002	Prosecution File History of U.S. Patent No. 11,672,803 (without foreign references)
1003	Declaration of Hollis D. Showalter, Ph.D.
1004	Curriculum Vitae of Hollis D. Showalter, Ph.D.
1005	Declaration of Steven T. Rosen, M.D., F.A.C.P., FASCO, FAIMBE
1006	Curriculum Vitae of Steven T. Rosen, M.D., F.A.C.P., FASCO, FAIMBE
1007	Declaration of Sylvia D. Hall-Ellis, Ph.D.
1008	Curriculum Vitae of Sylvia D. Hall-Ellis, Ph.D.
1009	John C. Byrd, et. al. “Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia”, N. Eng. J. Med. 2013 July 4; 369(1): 32-42.
1010	Supplementary Appendix to John C. Byrd, et. al. “Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia”, N. Eng. J. Med. 2013 July 4; 369(1): 32-42.
1011	Protocol for John C. Byrd, et. al. “Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia”, N. Eng. J. Med. 2013 July 4; 369(1): 32-42.
1012	BRUKINSA Prescribing Information (Revised April 2023)
1013	BRUKINSA Prescribing Information (Revised Nov. 2019)
1014	IMBRUVICA Prescribing Information (Revised May 2023)
1015	IMBRUVICA Prescribing Information (Revised Aug. 2022)
1016	Prosecution File History of U.S. Provisional Application No. 61/351,130

<u>Exhibit</u>	<u>Description</u>
1017	Prosecution File History of U.S. Provisional Application No. 61/351,655
1018	Prosecution File History of U.S. Provisional Application No. 61/351,762
1019	Prosecution File History of U.S. Provisional Application No. 61/351,793
1020	Prosecution File History of U.S. Provisional Application No. 61/419,764
1021	Prosecution File History of U.S. Provisional Application No. 61/472,138
1022	Prosecution File History of U.S. Patent Application No. 13/153,317 (without foreign references)
1023	Prosecution File History of U.S. Patent Application No. 13/869,700
1024	U.S. Patent No. 9,801,881
1025	Prosecution File History of U.S. Patent No. 9,801,881 (without foreign references)
1026	U.S. Patent No. 10,016,435
1027	Prosecution File History of U.S. Patent No. 10,016,435 (without foreign references)
1028	U.S. Patent No. 10,478,439
1029	Prosecution File History of U.S. Patent No. 10,478,439 (without foreign references)
1030	U.S. Patent No. 10,653,696
1031	Prosecution File History of U.S. Patent No. 10,653,696 (without foreign references)
1032	U.S. Patent No. 10,751,342
1033	Prosecution File History of U.S. Patent No. 10,751,342 (without foreign references)
1034	U.S. Patent Publication No. 2015/0259354

<u>Exhibit</u>	<u>Description</u>
1035	U.S. Patent Publication No. 2019/0275037
1036	U.S. Patent Publication No. 2020/0140432
1037	<i>Reserved</i>
1038	PCT Patent Publication No. WO 2009/158571
1039	John C. Alexander, et. al. “Modern Drug Discovery & Development,” Clinical & Translational Sci., Principles of Human Research 2009; 361-380.
1040	Naomi Alpert, et. al. “Prevalence of Cytopenia in the Gen. Population—A Nat’l Health & Nutrition Examination Survey Analysis”, Frontiers in Oncology Nov. 2020; 10:579075.
1041	Brian J. Bender, et. al. “A practical guide to large-scale docking”, Nature Protocols Oct. 2021; 16:4799-4832.
1042	Dixit V. Bhalani, et. al., “Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics”, Biomedicines 2022, 10:1055.
1043	J.R. Brown, et. al. “Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia”, N. Eng. J. Med. 2023; 388:319-332.
1044	Chiara Brullo, et. al. “Btk Inhibitors: A Medicinal Chemistry & Drug Delivery Perspective”, Int’l J. of Molecular Sci. 2021; 22:7641.
1045	D.S. Chabot-Richards and T.I. George, “Leukocytosis”, Int’l J. Lab Hematology 2014; 26:279-288.
1046	Geoffrey M. Currie, “Pharmacology, Part 1: Introduction to Pharmacology & Pharmacodynamics”, Soc. of Nuclear Med. & Molecular Imaging June 2018; 46(2):81-86.
1047	Osmond J. D’Cruz, et. al. “Novel Bruton’s tyrosine kinase inhibitors currently in development”, OncoTargets & Therapy 2013; 6:161-176.

<u>Exhibit</u>	<u>Description</u>
1048	H. Yesid Estupiñán, et. al. “Comparative Analysis of BTK Inhibitors & Mechanisms Underlying Adverse Effects”, Frontiers in Cell & Developmental Biology March 2021; 9:630942.
1049	L. Garuti, et. al. “Irreversible Protein Kinase Inhibitors”, Current Medicinal Chem., 2011; 18:2981-2994.
1050	Yang Ge, et. al. “Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold”, ACS Med. Chem. Letters 2016; 7:1050-1055.
1051	Arianna Gennari, et. al. “Thiol-based michael-type addition. A systematic evaluation of its controlling factors”, Tetrahedron 2020; 76:131637.
1052	Arup K. Ghose, et. al. “Knowledge Based Prediction of Ligand Binding Modes & Rational Inhibitor Design for Kinase Drug Discovery”, J. Medicinal Chem. 2008; 51(17); 5149-5171.
1053	Yunhang Guo, et. al. “Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase”, J. Medicinal Chem. 2019; 62:7923-7940.
1054	Sarah E. M. Herman, et. al. “Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765”, Blood 2011; 117(23):6287-6296.
1055	Lee A. Honigberg, et. al. “The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy”, PNAS 2010; 107(29):13075-13080.
1056	Radek Jorda, et. al. “Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome”, Euro. J. Medicinal Chem. 2020; 204:112636
1057	Albert Liclican, et. al. “Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton’s tyrosine kinase reveals differences in on – and off – target inhibition”, BBA – General Subjects 2020; 1864:129531

<u>Exhibit</u>	<u>Description</u>
1058	IMBRUVICA Prescribing Information (Revised June 2016)
1059	Chadi Nabhan, MD and Steven T. Rosen, “Chronic Lymphocytic Leukemia: A Clinical Review”, J. Am. Med. Ass’n, Dec. 2014; 312(21):2265-2276, with Supplemental Data
1060	Zhengying Pan, et. al. “Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase”, ChemMedChem 2007; 2, 58-61.
1061	Lindsey E. Roeker, “Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia”, Blood Advances 2023; 7(16):4291-4301.
1062	Mark Sabat, “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design”, J. Med. Chem. 2021; 64:12893-12902.
1063	John F. Seymour, et. al. “Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial”, Blood 2023; 142(8):687-699.
1064	Juswinder Singh, et. al. “Targeted covalent drugs of the kinase family”, Current Opinion in Chem. Bio. 2010; 14:475-480.
1065	Simar Pal Singh, et. al. “Role of Bruton’s tyrosine kinase in B cells and malignancies”, Molecular Cancer 2018; 17:57.
1066	Frédérique St-Pierre and Shuo Ma, “Use of BTK Inhibitors in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance”, Blood & Lymphatic Cancer: Targets & Therapy 2022; 12:81-98.
1067	Duxin Sun, et. al. “Why 90% of clinical drug development fails and how to improve it?”, Acta Pharmaceutica Sinica B 2022; 12(7):3049-3062.
1068	Constantine S. Tam, et. al. “Phase 1 study of the selective BTK inhibitors zanubrutinib in B-cell malignancies and safety and efficacy evaluations in CLL”, Blood 2019; 134(11):851-859.

<u>Exhibit</u>	<u>Description</u>
1069	Constantine S. Tam, et. al. “Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib”, Expert Review of Clinical Pharmacology 2021; 14(11):1329-1344.
1070	Guanghui, Tang, et. al. “Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry”, Euro. J. Medicinal Chem. 2023; 259:115671.
1071	Bruno Tasso, et. al. “The Development of BTK Inhibitors: A Five-Year Update”, Molecules 2021; 26:7411.
1072	Fatih M. Uckun, “Clinical Potential of Targeting Bruton’s Tyrosine Kinase”, Int’l Reviews of Immunology 2008; 27:43-69.
1073	Faith M. Uckun and Sanjive Qazi, “Bruton’s tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity”, Expert Opinion 2010; 20(11):1457-1470.
1074	Wei Xu, et. al. “Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study”, J. Hematology & Oncology 2020; 13:48.
1075	Rula Zain and Mauno Vihinen, “Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors”, Frontiers in Immunology 2021; 12:694853.
1076	Datong Zhang, et. al. “Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases”, Molecules 2021; 26:4907.
1077	Jianming Zhang, et. al. “Targeting cancer with small molecule kinase inhibitors”, Nature reviews Jan. 2009; 9:28-39.
1078	Plaintiffs’ Post-Trial Proposed Findings of Fact with Respect to Defendants Alvogen Pine Brook LLC & Natco Pharma Ltd, in case titled <i>Pharmacyclics LLC v. CIPLA Ltd.</i> , (D. Del. No. 18-192 and 19-434, Jan. 5, 2021), ECF No. 332

<u>Exhibit</u>	<u>Description</u>
1079	Brief of Plaintiffs-Appellees Pharmacyclics LLC & Janssen Biotech, Inc., in case titled <i>Pharmacyclics LLC v. Alvogen</i> (Fed. Cir. No. 21-2270 Mar. 4, 2022), ECF No. 28
1080	IMBRUVICA Prescribing Information (Revised May 2016)
1081	IMBRUVICA Prescribing Information (Revised November 2013)
1082	“FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma”, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma
1083	BRUKINSA Prescribing Information (Revised January 2023)
1084	FDA letter to Pharmacyclics, Inc. re NDA application for Imbruvica (ibrutinib) capsules, dated Feb. 12, 2014, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205552Orig2s000ltr.pdf
1085	Leukemia information, https://www.ncbi.nlm.nih.gov/books/NBK560490/ (last updated Jan. 17, 2023)
1086	Non-Hodgkin Lymphoma information, https://www.ncbi.nlm.nih.gov/books/NBK559328/ (last updated Feb. 24, 2023)
1087	“NCCN Revamps Treatment Preferences in CLL / SLL”, CLL Society, Nov. 3, 2022, https://cllsociety.org/2022/11/nccn-revamps-treatment-preferences-in-ctl-sll/ (last updated Jan. 31. 2023)
1088	“Project Orbis: FDA approves acalabrutinib for CLL and SLL”, Food & Drug Admin, https://www.fda.gov/drugs/resources-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-ctl-and-sll
1089	“Brukinsa FDA Approval History”, Drugs.com, https://www.drugs.com/history/brukina.html (last updated Jan. 24, 2023)

<u>Exhibit</u>	<u>Description</u>
1090	“Imbruvica FDA Approval History”, Drugs.com, https://www.drugs.com/history/imbruvica.html (last updated Sept. 13, 2023)
1091	“Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States”, The ASCO Post, https://ascopost.com/news/april-2023/update-on-withdrawal-of-ibrutinib-accelerated-approvals-for-mcl-and-mzl-in-the-united-states/ (last updated Apr. 14, 2023)
1092	“Media Update: Patient enrollment of phase III tolebrutinib trials paused in the US”, Sanofi Jan. 30, 2022, https://www.sanofi.com/en/media-room/press-releases/2022/2022-06-30-05-30-00-2471767
1093	“A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (ALPINE)” Clinicaltrials.gov, https://clinicaltrials.gov/study/NCT03734016 (last updated Aug. 25, 2023)
1094	“Safety of PCI-32765 in Chronic Lymphocytic Leukemia”, Clinicaltrials.gov, https://clinicaltrials.gov/study/NCT01105247 (last updated Mar. 31, 2014)
1095	“Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma (PCYC-04753)”, Clinicaltrials.gov, https://clinicaltrials.gov/study/NCT00849654 (last updated May 22, 2013)
1096	2011-2020 Clinical Development Success Rates and Contributing Factors, Biotechnology Innovation Organization (February 2021)
1097	Selected chapters from “Comprehensive Heterocyclic Chemistry III”, Elsevier Ltd 2008, 1st edition.
1098	U.S. Patent No. 11,672,803 Claim Listing
1099	Rajan Swami and Aliasgar Shahiwala, “Impact of physiochemical properties on pharmacokinetics of protein therapeutics”, Euro. J. Drug Metab Pharmacokinet 2013; 38:231-239.

<u>Exhibit</u>	<u>Description</u>
1100	January 9, 2024 office action rejection in U.S. Patent Application 18/180,064
1101	November 21, 2023 Information Disclosure Statement in U.S. Patent Application 18/180,064
1102	Affidavit of Nathaniel E Frank-White (including a printout of the 2015 archived version of the Byrd Protocol (Ex. 1011)), dated November 16, 2023
1103	Affidavit of Nathaniel E Frank-White (including a printout of the 2016 archived version of the IMBRUVICA Label (Ex. 1058)), dated November 16, 2023
1104	Affidavit of Nathaniel E Frank-White (including a printout of the 2013 archived version of the New England Journal of Medicine website, with links to the Byrd reference (Ex. 1009) and its Supplementary Material (Ex. 1010)), dated November 16, 2023
1105	Reply Declaration of Dr. Hollis D. Showalter, Ph.D.
1106	Reply Declaration of James M. Veal, Ph.D.
1107	Curriculum Vitae of James M. Veal, Ph.D.
1108	WIPO Publication No. WO 2014/173289A1
1109	WIPO Publication No. WO 2016/007185A1
1110	Deposition Transcript of Michael J. Eck, M.D., Ph.D, taken on October 8, 2024
1111	Eck Deposition Exhibit 1 – Hong Wu, et. al. “Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia”, Leukemia Jan. 2016, 30(1):173-181.
1112	Eck Deposition Exhibit 2 – U.S. Patent No. 11,672,803 (with annotations by witness)

<u>Exhibit</u>	<u>Description</u>
1113	Eck Deposition Exhibit 3 – Screenshot of IMBRUVICA native file, Maestro - Scratch Project (from EX2113)
1114	Eck Deposition Exhibit 4 – Screenshot of IMBRUVICA native file, Maestro - Scratch Project (from EX2114)
1115	Eck Deposition Exhibit 5 – Screenshot of BRUKINSA native file, Maestro - Scratch Project (from EX2113)
1116	Eck Deposition Exhibit 6 – Screenshot of Compound 7 (Zhang 2020) native file, Maestro (from EX2114)
1117	Deposition Transcript of David A. Scott, taken on September 27, 2024
1118	Scott Deposition Exhibit 1 – Christoph Gorgulla, et. al. “An open-source drug discovery platform enables ultra-large virtual screens”, Nature April 2020; 580(7805): 663-668.
1119	Deposition Transcript of Stephen E. Spurgeon, M.D., taken on September 6, 2024
1120	Spurgeon Deposition Exhibit 1 – Pallawi Torka, et. al. “Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma”, Blood Cancer Journal 2023, 13:9.
1121	Spurgeon Deposition Exhibit 2 – Laura Samples, et. al. “Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study”, Blood Advances 2024, 8(9):2085-2093.
1122	Syed Awais Attique, et. al. “A Molecular Docking Approach to Evaluate the Pharmacological Properties of Natural and Synthetic Treatment Candidates for Use against Hypertension”, Int’l J. Env’tl. Research & Public Health 2019, 16, 923.
1123	Ahmed H.H. Bakheit, et. al., Chapter 1. Azithromycin, “Profiles of Drug Substances, Excipients, and Related Methodology” 2014, Vol. 39, 1-40.

<u>Exhibit</u>	<u>Description</u>
1124	Miklos Feher and Christopher I. Williams, “Numerical Errors and Chaotic Behavior in Docking Simulations”, J. of Chem. Info. & Modeling 2012, 52, 724-738.
1125	Supplementary Material for the manuscript “Numerical Errors and Chaotic Behavior in Docking Simulations”, by Miklos Feher and Christopher I. Williams
1126	Kun-Yi Hsin, et. al., “Combining Machine Learning Systems and Multiple Docking Simulation Packages to Improve Docking Prediction Reliability for Network Pharmacology”, PLOS ONE Dec. 2013, 8(12):1-9.
1127	Dian Jiao, et. al. “Calculation of protein-ligand binding free energy by using a polarizable potential”, PNAS April 2008, 105(17):6290-6295.
1128	<i>Reserved</i>
1129	Xuan-Yu Meng, et. al., “Molecular Docking: A powerful approach for structure-based drug discovery”, Curr Comput Aided Drug Des., June 2011, 7(2): 146-157.
1130	Dariusz Plewczynski, et. al., “Can We Trust Docking Results? Evaluation of Seven Commonly Used Programs on PDBbind Database”, Wiley Periodicals, Inc., June 2010, 742-755.
1131	<i>Reserved</i>
1132	David Ramirez and Julio Caballero, “Is it Reliable to Use Common Molecular Docking Methods for Comparing the Binding Affinities of Enantiomer Pairs for Their Protein Target?”, Int’l J. of Molecular Scis. 2016, 17, 525.
1133	Robert Roskoski, Jr., “Rule of five violations among the FDA-approved small molecule protein kinase inhibitors”, Pharmacological Research 191 (2023) 106774.
1134	“What is the difference between GlideScore and Emodel, and which should I use for ranking poses?”, Schrödinger, Inc. (July 29, 2022), https://support.schrodinger.com/s/article/1027 .

<u>Exhibit</u>	<u>Description</u>
1135	“Dramatically improving hit rates with a modern virtual screening workflow”, Schrödinger, Inc. (2023).
1136	“Docking and Scoring”, Schrödinger, Inc., https://www.schrodinger.com/life-science/learn/white-papers/docking-and-scoring/ (last visited October 21, 2024).
1137	Sara Shamsian, et. al., “Bencchmarking different docking protocols for predicting the binding poses of ligands complexed with cyclooxygenase enzymes and screening chemical libraries”, Bioimpacts 2024, 14(2):29955.
1138	Ermias Mergia Terefe and Arabinda Ghosh, “Molecular Docking, Validation, Dynamics Simulations, and Pharmacokinetic Prediction of Phytochemicals Isolated From <i>Croton dichogamus</i> Against the HIV-1 Reverse Transcriptase”, Bioinformatics & Biology Insights 2022, Vol. 16:1-20.
1139	Vincente Zoete, et. al. “Docking, virtual high throughput screening and in silico fragment-based drug design”, J. Cellular & Molecular Med. 2009, 13(2):238-248.
1140	Ibrutinib (Glide Modeling)
1141	Zanubrutinib (Glide Modeling)
1142	Compound 81, WO’289 (Glide Modeling)
1143	Compound 9, WO’185 (Glide Modeling)
1144	Compound 30, 446 Patent (Glide Modeling)
1145	Compound 122, 446 Patent (Glide Modeling)
1146	Compounds with Reported IC50 Values (Glide Modeling)
1147	Structure E2, 803 Patent (Glide Modeling)
1148	Structure E3, 803 Patent (Glide Modeling)

<u>Exhibit</u>	<u>Description</u>
1149	Structure E4, 803 Patent (Glide Modeling)
1150	Formula I, 820 Patent (Glide Modeling)
1151	PDB - 2QD9 (Glide Modeling)
1152	PDB - 5TR6 and 5TT7 (Glide Modeling)
1153	RCSB PDB - 2QD9_ P38 Alpha Map Kinase inhibitor based on heterobicyclic scaffolds, https://www.rcsb.org/structure/2qd9
1154	RCSB PDB - 5TR6_ Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK), https://www.rcsb.org/structure/5tr6
1155	RCSB PDB - 5TT7_ Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK), https://www.rcsb.org/structure/5tt7
1156	Zanubrutinib and Compound 81, WO'289 (Glide Modeling)
1157	Elizabeth H. Krenske et. al., "Transition States and Energetics of Nucleophilic Additions of Thiols to Substituted α,β -Unsaturated Ketones: Substituent Effects Involve Enone Stabilization, Product Branching, and Solvation", J. Org. Chem. 2011, 76, 5074–5081.
1158	Supplementary Material for "Transition States and Energetics of Nucleophilic Additions of Thiols to Substituted α,β -Unsaturated Ketones: Substituent Effects Involve Enone Stabilization, Product Branching, and Solvation", by Elizabeth H. Krenske, et. al.
1159	Glide project native file containing Glide modeling results discussed in EX1106, ¶¶114-161 <i>[served, not filed]</i>
1160	Declaration of Priyata Y. Patel in Response to Patent Owner's Objections to Petitioner's Evidence <i>[served, not filed]</i>

Dated: November 21, 2024

Respectfully submitted,

/Priyata Y. Patel/

Elizabeth S. Weiswasser (Reg. No. 55,721)

Anish R. Desai (Reg. No. 73,760)

Kathryn Leicht (Reg. No. 80,620)

WEIL, GOTSHAL & MANGES LLP

767 Fifth Avenue

New York, NY 10153

T: 212-310-8000

F: 212-310-8007

E: BeiGene.PGR.Service@weil.com

Priyata Y. Patel (Reg. No. 76,861)

WEIL, GOTSHAL & MANGES LLP

2001 M Street NW, Suite 600

Washington, DC 20036

T: 202-682-7000

F: 202-857-0940

E: BeiGene.PGR.Service@weil.com

David I. Berl

Reg. No. 72,751

WILLIAMS & CONNOLLY LLP

680 Maine Ave SW

Washington, DC 20024

T: 202-434-5000

E: BeiGene.PGR.Service@weil.com

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that on November 21, 2024, a true and correct copy of PETITIONERS' UPDATED EXHIBIT LIST and accompanying Exhibit 1160 was sent via electronic mail, upon the following:

David P. Frazier
Michael A. Morin
Latham & Watkins LLP
555 Eleventh Street, NW, Ste. 1000
Washington, D.C. 20004-1304
Telephone: 202.637.2200
david.frazier@lw.com
michael.morin@lw.com

Brenda L. Danek
Latham & Watkins LLP
330 North Wabash Avenue, Suite 2800
Chicago, IL 60611
Telephone: 312.876.7646
brenda.danek@lw.com
AbbVieBeiGene.LWteam@lw.com

/Timothy J. Andersen/
Timothy J. Andersen
IP Case Manager
Weil, Gotshal & Manges LLP
2001 M Street, N.W., Suite 600
Washington, D.C. 20036
202-682-7000
timothy.andersen@weil.com